PriceTargets.com logo

Qiagen - QGEN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $47.09
  • Forecasted Upside: 37.54%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$34.24 As of 05/1/2026 04:59 PM ET
▼ -0.015 (-0.04%)

This chart shows the closing price for QGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Qiagen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QGEN

Analyst Price Target is $47.09
▲ +37.54% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Qiagen in the last 3 months. The average price target is $47.09, with a high forecast of $59.00 and a low forecast of $38.00. The average price target represents a 37.54% upside from the last price of $34.24.

This chart shows the closing price for QGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in Qiagen. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/10/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/8/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
4/4/2026
  • 1 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2026

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/30/2026Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy$43.00
4/29/2026BarclaysSet TargetEqual Weight ➝ Equal Weight$44.00 ➝ $38.00
4/29/2026Robert W. BairdSet TargetNeutral ➝ Outperform$53.00 ➝ $43.00
4/29/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
4/29/2026Robert W. BairdUpgradeHold ➝ Strong-Buy$43.00
4/29/2026JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$60.00 ➝ $45.00
4/29/2026CitigroupLower TargetNeutral ➝ Neutral$55.00 ➝ $38.00
4/14/2026BarclaysSet TargetOverweight ➝ Equal Weight$44.00
4/14/2026BarclaysDowngradeOverweight ➝ Equal Weight$44.00
3/27/2026Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
3/13/2026Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$54.00
3/9/2026Zacks ResearchDowngradeHold ➝ Strong Sell
2/9/2026UBS GroupSet Target$52.00
2/6/2026Robert W. BairdSet Target$53.00
2/6/2026TD CowenReiterated RatingHold ➝ Hold
2/6/2026Stifel NicolausSet TargetHold ➝ Hold$45.00 ➝ $50.00
2/6/2026BarclaysSet TargetOverweight ➝ Overweight$58.00
2/6/2026JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$55.00 ➝ $60.00
2/6/2026CitigroupLower TargetNeutral ➝ Neutral$55.40 ➝ $55.00
2/5/2026Jefferies Financial GroupReiterated RatingBuy ➝ Buy$59.00
1/22/2026Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$52.00 ➝ $54.00
1/21/2026UBS GroupReiterated RatingNeutral ➝ Neutral
12/29/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/22/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/15/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/15/2025BarclaysReiterated RatingOverweight ➝ Overweight$55.79 ➝ $57.89
12/11/2025CitigroupDowngradeBuy ➝ Neutral$57.89 ➝ $52.63
12/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/1/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/25/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/19/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/13/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/8/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
10/2/2025BarclaysSet TargetOverweight ➝ Overweight$57.89 ➝ $55.79
9/27/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
8/7/2025TD CowenReiterated RatingHold ➝ Hold
8/7/2025UBS GroupBoost TargetNeutral ➝ Neutral$50.53 ➝ $52.63
6/26/2025Bank of AmericaBoost TargetBuy ➝ Buy$52.63 ➝ $55.79
6/24/2025BarclaysInitiated CoverageOverweight$57.89
4/21/2025Robert W. BairdBoost TargetNeutral ➝ Neutral$44.21 ➝ $45.26
4/4/2025Rothschild & Co RedburnDowngradeBuy ➝ Neutral
2/19/2025Robert W. BairdDowngradeStrong-Buy ➝ Hold$54.74 ➝ $44.21
2/7/2025UBS GroupLower TargetNeutral ➝ Neutral$52.63 ➝ $50.53
1/6/2025Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$51.17 ➝ $49.12
12/10/2024Jefferies Financial GroupReiterated RatingHold ➝ Buy$42.98 ➝ $55.26
10/17/2024HSBCUpgradeHold
10/17/2024HSBCDowngradeBuy ➝ Hold$50.15
8/2/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$50.15 ➝ $53.22
6/27/2024Wolfe ResearchUpgradePeer Perform ➝ Outperform$51.17
6/18/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$53.22 ➝ $55.26
5/1/2024Stifel NicolausLower TargetHold ➝ Hold$56.29 ➝ $46.05
2/16/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$50.64 ➝ $52.19
2/8/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$51.17 ➝ $53.22
2/8/2024CitigroupLower TargetBuy ➝ Buy$63.31 ➝ $61.40
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$47.48 ➝ $52.75
12/19/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$46.42
12/13/2023Wolfe ResearchInitiated CoveragePeer Perform
12/7/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$52.75
11/2/2023UBS GroupLower TargetNeutral ➝ Neutral$50.64 ➝ $44.31
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$58.03 ➝ $52.75
9/29/2023HSBCLower Target$67.52 ➝ $60.14
9/26/2023CitigroupReiterated RatingBuy ➝ Buy$63.30
9/11/2023Robert W. BairdInitiated CoverageOutperform$52.75
8/9/2023UBS GroupLower TargetNeutral ➝ Neutral$52.75 ➝ $50.64
5/23/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
5/5/2023UBS GroupLower Target$54.86 ➝ $52.75
2/9/2023UBS GroupBoost TargetNeutral$52.75 ➝ $54.86
2/9/2023CitigroupBoost TargetBuy$58.03 ➝ $63.30
11/11/2022Berenberg BankBoost Target€56.88 ➝ €57.61
11/9/2022CitigroupLower TargetBuy$65.41 ➝ $58.03
11/8/2022William BlairReiterated RatingMarket Perform
10/18/2022Morgan StanleyInitiated CoverageEqual Weight
10/10/2022Oddo BhfDowngradeOutperform ➝ Neutral
1/17/2022DZ BankUpgradeHold ➝ Buy
12/14/2021Wells Fargo & CompanyBoost TargetEqual Weight$61.19 ➝ $63.30
11/26/2021Kepler Capital MarketsDowngradeHold$51.70
10/21/2021Norddeutsche LandesbankReiterated RatingHold
10/14/2021Rothschild & Co RedburnInitiated CoverageBuy
7/14/2021CheuvreuxDowngradeBuy ➝ Hold$52.26
7/14/2021Kepler Capital MarketsDowngradeBuy ➝ Hold$52.26
7/14/2021CitigroupLower TargetBuy$68.58 ➝ $61.19
7/9/2021Kepler Capital MarketsUpgradeBuy$53.81
6/25/2021DZ BankReiterated RatingNeutral
6/17/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
6/11/2021Berenberg BankReiterated RatingBuy
6/8/2021The Goldman Sachs GroupReiterated RatingBuy
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$54.86
5/4/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
(Data available from 5/4/2021 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 2 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/4/2026
  • 3 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 9 very positive mentions
  • 21 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
Mentions as of
5/4/2026

Current Sentiment

  • 9 very positive mentions
  • 21 positive mentions
  • 5 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Qiagen logo
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Read More

Today's Range

Now: $34.24
Low: $33.56
High: $34.84

50 Day Range

MA: $41.78
Low: $33.61
High: $49.81

52 Week Range

Now: $34.24
Low: $33.17
High: $57.81

Volume

1,439,207 shs

Average Volume

2,041,159 shs

Market Capitalization

$7.05 billion

P/E Ratio

16.98

Dividend Yield

0.77%

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Qiagen?

The following Wall Street analysts have issued reports on Qiagen in the last year: Bank of America Corporation, Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., Robert W. Baird, Stifel Nicolaus, TD Cowen, UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for QGEN.

What is the current price target for Qiagen?

0 Wall Street analysts have set twelve-month price targets for Qiagen in the last year. Their average twelve-month price target is $47.09, suggesting a possible upside of 37.5%. Jefferies Financial Group Inc. has the highest price target set, predicting QGEN will reach $59.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $38.00 for Qiagen in the next year.
View the latest price targets for QGEN.

What is the current consensus analyst rating for Qiagen?

Qiagen currently has 7 hold ratings, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for QGEN.

What other companies compete with Qiagen?

Other companies that are similar to Qiagen include Insmed, Revolution Medicines, BioNTech, Moderna and Roivant Sciences. Learn More about companies similar to Qiagen.

How do I contact Qiagen's investor relations team?

Qiagen's physical mailing address is HULSTERWEG 82, VENLO P7, 5912. The company's listed phone number is (177) 355-6600 and its investor relations email address is [email protected]. The official website for Qiagen is www.qiagen.com. Learn More about contacing Qiagen investor relations.